FSTL3 and pulmonary arterial hypertension: Sera from two validation cohorts were then used to test the discrimination of FSTL3 and MDK for lcSSc-PAH and although some of the patients had already received treatment, a significant increase in both FSTL3 and MDK concentrations was found in lcSSc with PAH vs. those without PAH.